BLS.AU Bls Pharmaceuticals Limited

Healthcare Biotechnology Australian Securities Exchange
1.02 AUD
Close of Nov 1, 2026
0.3500 1.30
Market cap
AUD 242M
P/E
14.6x
P/B
7.78x
ROE
49.5%
Dividend yield
-
Fundamental score
2.1/5

Ratios use the latest price and the fiscal year ending Jun 2026.

Is BLS.AU undervalued?

Graham number
Price1.02
Graham value0.4554
Premium125.1%

BLS.AU trades 125.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Bls Pharmaceuticals Limited fundamental analysis

9 of 22 checks passed

ROE 2/2

High return on equity (49.5%), above 20%.

ROA 1/1

Return on assets (29.6%) is above the industry median (-51.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share history is shorter than 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 0/1

Earnings growth cannot be compared with the industry.

Revenue Growth 2/2

Revenue grew 143.1% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (6.2%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 0/1

Operating cash flow does not cover 20% of total debt.

Interest Coverage 1/1

EBIT is 34.0x against interest expense, well covered.

PE vs Market 1/1

PE (14.6x) is below the market median (15.0x).

PE vs Industry 1/1

PE (14.6x) is below the industry median (16.3x).

PBV 0/1

Price to book (7.8x) is above the industry median (4.4x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 114.0, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Bls Pharmaceuticals Limited stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Bls Pharmaceuticals Limited

BLS Pharmaceuticals Limited manufactures, imports, exports, and supplies controlled drugs and prescription medicines in Australia, the United Kingdom, Europe, and Japan. It operates through Manufacture/Sales Australia, Plant Based/UK/EU/JPN/AUS, and Wholesale PCC/USA segments. The Manufacture/Sales Australia segment engages in the manufacture and wholesale supply of preventive and novel medicines, cannabis, psilocybin, and MDMA under BLS. The Plant Based/UK/EU/JPN/AUS segmen…

Full company profile